Yan Tristan D, Padang Ratnasari, Morris David L
St George Hospital, Kogaragh, NSW Australia.
J Am Coll Surg. 2006 Jan;202(1):100-11. doi: 10.1016/j.jamcollsurg.2005.08.026. Epub 2005 Nov 2.
Only a minority of patients are suitable for liver resection for colorectal liver metastases. Cryotherapy was the first widely used ablative technique, achieving a median survival of more than 2 years. Patient selection is important, but the prognostic criteria have been controversial. The combined treatment modality of cryotherapy, resection, and hepatic arterial chemotherapy has been used in treating unresectable liver disease. Many centers would not surgically treat patients with multiple (five or more lesions) bilateral liver metastases. This series reports on longterm results after cryotherapy and hepatic arterial chemotherapy with or without liver resection in 224 patients with colorectal liver metastases, especially in patients with multiple bilateral liver disease, and identifies important prognostic determinants for survival.
A longterm retrospective analysis was performed of prospectively collected clinical data of 224 patients with colorectal liver metastases who received cryotherapy and hepatic arterial chemotherapy with or without resection. Morbidity, mortality, recurrence, and survival rates were reported and Kaplan-Meier and Cox regression analysis were used to identify prognostic indicators.
Median length of followup was 26 months (range 1 to 130 months). Perioperative mortality rate was 0.4% and morbidity rate was 21%. Cryosite, remaining liver, and extrahepatic recurrence rates were 39%, 62%, and 67%, respectively. Median survival was 31 months (range 1 to 130 months) with 1-, 3-, and 5-year survival rates of 87%, 43%, and 23%, respectively. Ninety-one patients had five or more bilateral lesions. Median and 5-year survival was 31 months (2 to 88 months) and 26%, respectively. Four factors were independently associated with favorable survival outcomes: cryotherapy with resection, complete tumor eradication, low pre- and postoperative CEA levels.
Cryotherapy and hepatic arterial chemotherapy with or without resection can achieve long survival advantage in patients with unresectable colorectal liver metastases.
仅有少数患者适合对结直肠癌肝转移灶进行肝切除术。冷冻疗法是首个被广泛应用的消融技术,其使患者的中位生存期超过2年。患者选择很重要,但预后标准一直存在争议。冷冻疗法、切除术及肝动脉化疗的联合治疗方式已被用于治疗无法切除的肝脏疾病。许多中心不会对患有多发(五个或更多病灶)双侧肝转移的患者进行手术治疗。本系列报道了224例结直肠癌肝转移患者在接受冷冻疗法及肝动脉化疗(无论是否行肝切除术)后的长期结果,尤其关注了患有多发双侧肝脏疾病的患者,并确定了生存的重要预后决定因素。
对224例接受冷冻疗法及肝动脉化疗(无论是否行切除术)的结直肠癌肝转移患者的前瞻性收集的临床数据进行长期回顾性分析。报告了发病率、死亡率、复发率及生存率,并采用Kaplan-Meier法和Cox回归分析来确定预后指标。
中位随访时间为26个月(范围1至130个月)。围手术期死亡率为0.4%,发病率为21%。冷冻消融部位、残余肝脏及肝外复发率分别为39%、62%和67%。中位生存期为31个月(范围1至130个月),1年、3年和5年生存率分别为87%、43%和23%。91例患者有五个或更多双侧病灶。中位生存期和5年生存率分别为31个月(2至88个月)和26%。四个因素与良好的生存结果独立相关:冷冻疗法联合切除术、肿瘤完全清除、术前和术后CEA水平较低。
冷冻疗法及肝动脉化疗(无论是否行切除术)可使无法切除的结直肠癌肝转移患者获得长期生存优势。